Ra Pharma also granted the underwriters a 30-day option to purchase up to an additional 1,258,064 shares of its common stock.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately USD 130m, excluding any exercise of the underwriters' option to purchase additional shares.
All of the shares in the offering are to be sold by Ra Pharma.
Jefferies, BMO Capital Markets, and Stifel are acting as joint book-running managers for the offering. Guggenheim Securities is acting as lead manager, and Raymond James is acting as co-manager.
The offering is expected to close on or about December 14, 2018, subject to customary closing conditions.
Ra Pharma intends to use the net proceeds from the offering, in addition to its existing cash resources, to fund the clinical development of zilucoplan, including the Phase 3 clinical program in gMG and the advancement of other pipeline programs, and for working capital and other general corporate and administrative expenses.
Ra Pharmaceuticals is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for complement-mediated diseases. The company discovers and develops peptides and small molecules to target key components of the complement cascade.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval